MD Anderson Cancer Center Uses Velos eResearch

Thursday, May 12, 2011 General News
Email Print This Page Comment bookmark
Font : A-A+

Clinical Trial Management System to be Deployed throughout Enterprise

FREMONT, Calif., May 12, 2011 /PRNewswire/ -- Velos, Inc., the trusted leader in clinical trial management systems for

large academic medical centers and research institutions of all sizes, today announced an agreement with The University of Texas MD Anderson Cancer Center. The agreement calls for enterprise-wide installation of its flagship product, Velos eResearch. Installation is now underway with plans for production use in 2012.

MD Anderson initiates at least 1000 clinical studies each year and will deploy Velos eResearch. Currently, data is dispersed in many different applications and departments, requiring significant time and effort to build, submit, approve and complete a protocol.

About Velos

Velos is the trusted platform for clinical research and specialized medical records. Velos products are used by customers to manage all aspects of clinical research. Its products are used in medical specialties to manage distinctive, complex medical records. Velos delivers its products both for customer installation and as services on the Internet. Solutions from Velos include: Velos eResearch for clinical trial management, data capture, budgeting, and billing; Velos eIRB and Compliance solutions; Velos eSample for bio-specimen collection, tracking, and repository management; Velos eMaven for integration; and Velos specialty solutions in solid organ transplant, cell transplant, dialysis, and cardiology, among others. Founded in 1996, Velos is privately held with headquarters in Fremont, California.  For more information, visit www.velos.com.

This press release may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements.

SOURCE Velos, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store